Biotech

All Articles

FDA places Kezar lupus test in hold following 4 client fatalities

.The FDA has actually positioned Kezar Lifestyle Sciences' lupus test on hold after the biotech warn...

Phase 3 Intellectual Stone test attacks SMA objective, sending stock up 200%

.A stage 3 test of Historian Stone's vertebral muscle atrophy (SMA) prospect has struck its own prim...

CAMP 4 is newest to eye IPO, while Upstream spells out $182M plan

.RNA biotech CAMP4 Rehabs has marked out plans for a $67 million IPO, along with inflammation-focuse...

Galecto buys leukemia drug, loses bone cancer cells resource in pivot

.A year after the failure of an idiopathic lung fibrosis applicant sent out Galecto on a search for ...

Judo throws down $100M to knock out kidney condition

.Taking the floor covering is Judo Bio, an ambitious biotech armed along with $one hundred million t...

AstraZeneca pays for CSPC $100M for preclinical heart disease drug

.AstraZeneca has actually paid off CSPC Drug Team $one hundred thousand for a preclinical heart dise...

Zephyrm seeks Hong Kong IPO to money stage 3 cell treatment trials

.Zephyrm Bioscience is actually gusting toward the Hong Kong stock market, submitting (PDF) for an I...

Frazier Lifestyle Sciences collects $630M for tiny, mid-cap biotechs

.Frazier Lifespan Sciences has actually sourced an even further $630 thousand for its fund concentra...

GigaGen amasses as much as $135M BARDA money to beat botulism

.Antitoxin fanatic GigaGen, a subsidiary of Spanish biopharma Grifols, is ramping up its technology ...

GPCR firm Septerna declare IPO on strength of preclinical data

.Septerna will figure out how a biotech without "any sort of meaningful clinical records" fares in t...